Absence of TGF-βRII predicts bone and lung metastasis and is associated with poor prognosis in stage III breast tumors

Article type: Research Article

Authors: Paiva, Carlos Eduardo^{a; *} | Serrano, Sérgio Vicente^a | Paiva, Bianca Sakamoto Ribeiro^b | Scapulatempo-Neto, Cristovam^d | Soares, Fernando Augusto^e | Rogatto, Silvia Regina^{c; e} | Marques, Mariângela Esther Alencar^f

Affiliations: [a] Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil | [b] Barretos Cancer Hospital, Teaching and Research Institute, Barretos, São Paulo, Brazil | [c] NeoGene Laboratory, Department of Urology, São Paulo State University, Botucatu, São Paulo, Brazil | [d] Department of Pathology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil | [e] Department of Pathology, A. C. Camargo Cancer Treatment and Research Center, Sao Paulo, Brazil | [f] Department of Pathology, São Paulo State University, Botucatu, São Paulo, Brazil

Correspondence: [*] Corresponding author: Carlos Eduardo Paiva, Fundação Pio XII, Hospital de Câncer de Barretos, Departamento de Oncologia Clínica. Rua Antenor Duarte Villela, 1331, Bairro Dr. Paulo Prata, Barretos-SP, CEP: 14784-400, Brazil. Tel.: +55 17 33216600; E-mail: [email protected]; [email protected].

Abstract: In the case of operated breast cancer (BC), prognostic markers help to determine if the patient needs additional treatment and predictive markers help the clinician to decide which treatment to use. Thus, a better knowledge of known predictive and prognostic markers and the identification of new markers, may improve the treatment of BC patients. The transforming growth factor-beta type II receptor (TGF-βRII), a main receptor of transforming growth factor beta pathway, is a potential new prognostic marker. The aims of the present study were to investigate both the predictive and prognostic impact of TGF-βRII in BC samples. TGF-βRII protein expression was evaluated using immunohistochemistry on a tissue microarray containing 110 TNM stage III BC samples obtained prior to doxorubicin-based neoadjuvant chemotherapy (NAC). Our results demonstrate that TGF-βRII did not predict the response to NAC. On the other hand, an association between TGF-βRII-negative tumor and higher risk of metastasis to lungs and bones was verified. TGF-βRII negativity was an independent prognostic factor for decreased disease-free and overall survival.

Keywords: Breast cancer, survival, TGF-βRII, metastasis, prognostic marker

DOI: 10.3233/CBM-2012-00281

Journal: Cancer Biomarkers, vol. 11, no. 5, pp. 209-217, 2012